Nika Pharmaceuticals, Inc. (OTCQB: NIKA) entered into a consultancy agreement with MD Global Partners LLC, a Manhattan‑based investment bank, to provide advisory services that include capital‑raising assistance, growth initiatives, and due‑diligence support for potential transactions. The partnership is intended to help NIKA prepare for the next stages of its development, particularly as it approaches the operational launch of its Bulgarian manufacturing facility.
The agreement was announced on March 6 2026 and is a strategic move to strengthen NIKA’s advisory capabilities as it prepares to bring its Bulgarian plant online. MD Global Partners specializes in capital markets advisory, M&A, and growth capital for small to mid‑cap companies, with a track record in healthcare and pharmaceuticals. The partnership is expected to support NIKA’s capital‑raising efforts and strategic planning as the company moves toward full production and distribution.
CEO Dimitar Savov said, “As we prepare for the next stages of our development, it is important that we have an advisor with proven track record and expertise.” He added, “We expect significant growth once the production factory is operational and distribution begins, so the experience of MD Global Partners will be an important asset to our company. I believe that this is the start of a valuable long‑term partnership.”
Nika’s Bulgarian facility, which is expected to be completed by the end of the second quarter of 2025, represents a key milestone in the company’s expansion strategy. The consultancy agreement positions NIKA to leverage MD Global Partners’ expertise to secure financing, navigate regulatory requirements, and identify potential acquisition or partnership opportunities as it scales its operations.
No financial results or detailed terms of the agreement were disclosed in the announcement, but the partnership signals NIKA’s intent to strengthen its capital structure and accelerate growth as it transitions from development to commercial production.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.